New drug duo aims to beat bladder cancer without removing the bladder

NCT ID NCT06571708

First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 29 times

Summary

This study tests whether adding a new drug (fianlimab) to standard chemotherapy and immunotherapy can help adults with muscle-invasive bladder cancer achieve a complete response, meaning no cancer is found after treatment. About 36 participants will receive either the standard combination or the standard plus fianlimab. The goal is to preserve the bladder and avoid surgery if possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center/ New York Presbyterian Hospital

    RECRUITING

    New York, New York, 10032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.